Effect of Clcitriol in Ischemi stroke

Phase 2

Recruiting

Conditions: Ischemic Stroke.
Cerebral infarction due to thrombosis of unspecified precerebral artery
I63.00

Registration Number: IRCT20210101049905N1

Lead Sponsor: Hamedan University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 78

Inclusion Criteria

Age 18 to 85 years
Focal neurological disorder
Clinical diagnosis of acute ischemic stroke
Radiological findings of MRI and CT are consistent with the clinical diagnosis of acute hemisphere stroke
No other concomitant inflammatory disease
Do not take drugs other than standard ischemic stroke treatments that alter the levels of the factors under consideration.
No pregnancy and lactation
Patients who have been hospitalized for the first 24 hours after a stroke.
Patients suffering from ischemic stroke for the first time
Do not use any combination with antioxidant effects in the past month
No asthma and a history of anaphylactic shock

Exclusion Criteria

Evidence based on acute or chronic intracerebral hemorrhage and cerebral aneurysm
Existence of any etiology other than ischemia
Existence of any cognitive or behavioral disorders that lead to the patient not cooperating.
The patient's unwillingness to continue cooperating or taking the drug correctly
Drug intolerance and side effects
Consumption of any combination or drug with antioxidant effects except prescription drugs

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Erythrocyte Sedimentation Rate. Timepoint: At the beginning of the study and 3 days after the end of the medication. Method of measurement: Westergren.;C-Reactive Protein. Timepoint: At the beginning of the study and 3 days after the end of the medication. Method of measurement: latex agglutination.

Secondary Outcome Measures